- Home
- A-Z Publications
- Current Alzheimer Research
- Previous Issues
- Volume 19, Issue 7, 2022
Current Alzheimer Research - Volume 19, Issue 7, 2022
Volume 19, Issue 7, 2022
-
-
Complex Processes Underlying the Dynamic Changes of D-serine Levels in AD Brains
Authors: Xiance Ni and Hisashi MoriBackground: Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by extracellular β-amyloid (Aβ) plaques and cognitive impairments. D-Serine, produced by the enzyme serine racemase (SR) in the brain, functions as an endogenous co-agonist at the glycine-binding site of N-methyl-D-aspartate receptor (NMDAR), has been implicated in the pathophysiological progression of AD. Objectives: Evidence r Read More
-
-
-
Serine Racemase Expression Differentiates Aging from Alzheimer’s Brain
Authors: Shengzhou Wu, Jing Zhou, He Zhang and Steven W. BargerAging is an inevitable process characterized by progressive loss of physiological integrity and increased susceptibility to cancer, diabetes, cardiovascular, and neurodegenerative diseases; aging is the primary risk factor for Alzheimer’s disease (AD), the most common cause of dementia. AD is characterized by brain pathology, including extracellular deposition of amyloid aggregation and intracellular accumulati Read More
-
-
-
Comparing Medial Temporal Atrophy Between Early-Onset Semantic Dementia and Early-Onset Alzheimer's Disease Using Voxel-Based Morphometry: A Multicenter MRI Study
Background: Early-onset Semantic dementia (EOSD) and early-onset Alzheimer's disease (EOAD) are often difficult to clinically differentiate in the early stages of the diseases because of the overlaps of clinical symptoms such as language symptoms. We compared the degree of atrophy in medial temporal structures between the two types of dementia using the voxel-based specific regional analysis system for Alzheimer’s d Read More
-
-
-
Human microRNA-4433 (hsa-miR-4443) Targets 18 Genes to be a Risk Factor of Neurodegenerative Diseases
Authors: Xing Ge, Tingting Yao, Chaoran Zhang, Qingqing Wang, Xuxu Wang and Li-Chun XuBackground: Neurodegenerative diseases, such as Alzheimer's disease patients (AD), Huntington's disease (HD) and Parkinson’s disease (PD), are common causes of morbidity, mortality, and cognitive impairment in older adults. Objective: We aimed to understand the transcriptome characteristics of the cortex of neurodegenerative diseases and to provide an insight into the target genes of differently expressed micr Read More
-
-
-
Novel PSEN1 (P284S) Mutation Causes Alzheimer's Disease with Cerebellar Amyloid β-Protein Deposition
Authors: Mingrong Xia, Chenhao Gao, Huayuan Wang, Junkui Shang, Ruijie Liu, Yang You, Weizhou Zang and Jiewen ZhangBackground/Objective: AD-associated PSEN1 mutations exhibit high clinical heterogeneity. The discovery of these mutations and the analysis of their associations with cases such as EOAD should be critical to understanding AD's pathogenesis. Methods: We performed clinical analysis, neuroimaging, target region capture and high-throughput sequencing, and Sanger sequencing in a family of 3 generations. The underlyi Read More
-
-
-
RNA Hypomethylation and Unchanged DNA Methylation Levels in the Cortex of ApoE4 Carriers and Alzheimer’s Disease Subjects
Authors: Wei-Bin Shen, James J. Yang and Peixin YangBackground: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, and ApoE4 variants are significant risk factors for AD. Epigenetic modifications are involved in AD pathology. However, it is unclear whether DNA/RNA methylation plays a role in AD pathology, and dysregulation of DNA/RNA methylation occurs in ApoE4 carriers. Objective: The present study aimed to determine whether dysregulatio Read More
-
-
-
Comparative Bioavailability Study of a Novel Multi-Day Patch Formulation of Rivastigmine (Twice Weekly) with Exelon® Transdermal Patch (Daily)- A Randomized Clinical Trial
Authors: Bjoern Schurad, Cornelius Koch, Barbara Schug, Adelaida Morte, Anna Vaqué, Rafael De la Torre and Marc IniestaBackground: Rivastigmine, a reversible AChEI for symptomatic treatment of mild to moderately severe Alzheimer’s dementia, is administered once daily transdermal patches, enabling an easier and continuous drug delivery. A novel multi-day (twice week) patch formulation was developed with greater convenience for patients’ therapeutic management. Objective: To assess the bioequivalence under SS conditions of the multiple- Read More
-
Volumes & issues
-
Volume 21 (2024)
-
Volume 20 (2023)
-
Volume 19 (2022)
-
Volume 18 (2021)
-
Volume 17 (2020)
-
Volume 16 (2019)
-
Volume 15 (2018)
-
Volume 14 (2017)
-
Volume 13 (2016)
-
Volume 12 (2015)
-
Volume 11 (2014)
-
Volume 10 (2013)
-
Volume 9 (2012)
-
Volume 8 (2011)
-
Volume 7 (2010)
-
Volume 6 (2009)
-
Volume 5 (2008)
-
Volume 4 (2007)
-
Volume 3 (2006)
-
Volume 2 (2005)
-
Volume 1 (2004)
Most Read This Month
Article
content/journals/car
Journal
10
5
false
en

Most Cited Most Cited RSS feed
-
-
Cognitive Reserve in Aging
Authors: A. M. Tucker and Y. Stern
-
- More Less